The anti-leukemic effect and molecular mechanisms of novel hydroxamate and benzamide histone deacetylase inhibitors with 5-aza-cytidine

International Journal of Oncology

Volumn 38, Issue 5, 2011, Pages 1421-1425

  Liu, H B ^a,b   Mayes, P A ^b   Perlmutter, P ^b   McKendrick, J J ^c   Dear, A E ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c BOX HILL HOSPITAL   (Australia)

Author keywords

Benzamide; Demethylation; HDACi; Hydroxamate

Indexed keywords

ANTILEUKEMIC AGENT; AZACITIDINE; CASPASE 3; GELATINASE B; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; MCT 3; MESSENGER RNA; MOCETINOSTAT; NUCLEAR RECEPTOR NUR77; PROTEIN P15; PROTEIN P21; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL GROWTH; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA; LEUKEMOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; AZACITIDINE; BENZAMIDES; CASPASE 3; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HISTONE DEACETYLASE INHIBITORS; HL-60 CELLS; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA; MATRIX METALLOPROTEINASE 9; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 1;

EID: 79955031545     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.914     Document Type: Article

References (31)

1. Balasubramanian S, Verner E and Buggy JJ: Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett 280: 211-221, 2009.
2. Beckers T, Burkhardt C, Wieland H, Gimmnich P, Ciossek T, Maier T and Sanders K: Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer 121: 1138-1148, 2007. (Pubitemid 47101654)
3. Carew JS, Giles FJ and Nawrocki ST: Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 269: 7-17, 2008.
4. Dear AE, Mayes P, Liu HB and Perlmutter P: Novel conformational analogues of oxamflatin as histone deacetylase inhibitors. Org Biomol Chem 21: 3778-3784, 2006. (Pubitemid 44536090)
5. Stimson L, Wood V, Khan O, Fotheringham S and La Thangue NB: HDAC inhibitor-based therapies and haematological malignancy. Ann Oncol 20: 1293-1302, 2009.
6. Hitomi T, Matsuzaki Y, Yokota T, Takaoka Y and Sakai T: p15(INK4b) in HDAC inhibitor-induced growth arrest. FEBS Lett 554: 347-350, 2003. (Pubitemid 37412512)
7. Ocker M and Schneider-Stock R: Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol 39: 1367-1374, 2007. (Pubitemid 47031035)
8. Sonnemann J, Hartwig M, Plath A, Saravana Kumar K, Muller C and Beck JF: Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cells. Cancer Lett 232: 148-160, 2006. (Pubitemid 43170964)
9. Ailenberg M and Silverman M: Trichostatin A-histone deacetylase inhibitor with clinical therapeutic potential-is also a selective and potent inhibitor of gelatinase A expression. Biochem Biophys Res Commun 298: 110-115, 2002. (Pubitemid 35205394)
10. Liu LT, Chang HC, Chiang LC and Hung WC: Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res 263: 3069-3072, 2003.
11. 2+ signaling and c-fos and nur77 expression are associated with sodium butyrate-induced differentiation of C6 glioma cell. Chin J Physiol 43: 149-158, 2000.
12. Li QX, Ke N, Sundaram R and Wong-Staal F: NR4A1, 2, 3-an orphan nuclear hormone receptor family involved in cell apoptosis and carcinogenesis. Histol Histopathol 21: 533-540, 2006.
13. Mullican SE, Zhang S, Konopleva M, Ruvolo V, Andreeff M, Millbrant J and Conneely OM: Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. Nat Med 13: 730-735, 2007. (Pubitemid 46889752)
14. Liu HB, Voso MT, Gumiero D, Duong J, McKendrick JJ and Dear AE: The anti-leukemic effect of a novel histone deacetylase inhibitor MCT-1 and 5-aza-cytidine involves augmentation of Nur77 and inhibition of MMP-9 expression. Int J Oncol 34: 573-579, 2009.
15. Cameron EE, Bachman KE, Myohanen S, Herman JG and Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21: 103-107, 1999. (Pubitemid 29036293)
16. Lemaire M, Momparler LF, Farinha NJ, Bernstein M and Momparler RL: Enhancement of antineoplastic action of 5-aza-2′-deoxycytidine by phenylbutyrate on L1210 leukemic cells. Leuk Lymphoma 45: 147, 2004.
17. Shaker S, Bernstein M, Momparler LF and Momparler RL: Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2′-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. Leuk Res 27: 437-444, 2003. (Pubitemid 36287205)
18. Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H and Garcia-Manero G: Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid. Leuk Res 29: 739-748, 2005. (Pubitemid 40779480)
19. Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, Grever M, Galm O, Dauses T, Karp JE, Rudek MA, Zhao M, Smith BD, Manning J, Jiemjit A, Dover G, Mays A, Zwiebel J, Murgo A, Weng LJ and Herman JG: Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66: 6361-6369, 2006.
20. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM and Garcia-Manero G: Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110: 2302-2308, 2007. (Pubitemid 47523148)
21. Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, Kalita A, Liu J, Lu AH, Zhou NZ, Robert MF, Gillespie J, Wang JJ, Ste-Croix H, Rahil J, Lefebvre S, Moradei O, Delorme D, Macleod AR, Besterman JM and Li Z: MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 7: 759-768, 2008. (Pubitemid 351551029)
22. Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, Newsome WM, Miller WH Jr, Rousseau C, Kalita A, Bonfils C, Dubay M, Patterson TA, Li Z, Besterman JM, Reid G, Laille E, Martell RE and Minden M: Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 112: 981-989, 2008.
23. Kim YB, Lee KH, Sugita K, Yoshida M and Horinouchi S: Oxamflatin is a novel anti-tumor compound that inhibits mammalian histone deacetylase. Oncogene 18: 2461-2470, 1999. (Pubitemid 29206159)
24. Sato N, Maehara N, Su GH and Goggins M: Effects of 5-aza-2′- deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness. J Natl Cancer Inst 95: 327-330, 2003.
25. Chicoine E, Esteve PO, Robledo O, van Themsche C, Potworowski EF and St-Pierre Y: Evidence for the role of promoter methylation in the regulation of MMP-9 gene expression. Biochem Biophys Res Commun 97: 765-772, 2002. (Pubitemid 35230316)
26. Couillard J, Demers M, Lavoie G and St-Pierre Y: The role of DNA hypomethylation in the control of stromelysin gene expression. Biochem Biophys Res Commun 342: 1233-1239, 2006.
27. INK4B gene in myelodysplastic syndromes. Blood 90: 1403-1409, 1997.
28. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G and Wijermans P: Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine [decitabine] treatment. Blood 100: 2957-2964, 2002.
29. Odenike OM, Alkan S, Sher D, Godwin JE, Huo D, Brandt SJ, Green M, Xie J, Zhang Y, Vesole DH, Stiff P, Wright J, Larson RA and Stock W: Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin Cancer Res 14: 7095-7101, 2008.
30. Hitomi T, Matsuzaki Y, Yasuda S, Kawanaka M, Yogosawa S, Koyama M and Tantin D and Sakai T: Oct-1 is involved in the transcriptional repression of the p15(INK4b) gene. FEBS Lett 581: 1087-192, 2007.
31. Wallace DM, Donovan M and Cotter TG: Histone deacetylase activity regulates apaf-1 and caspase-3 expression in the developing mouse retina. Invest Ophthalmol Vis Sci 47: 2765-2772, 2006. (Pubitemid 351639745)